Category: CA Collaborations & Insights

Clinical Accelerator is delighted to celebrate five years of collaboration with Magenta Medical. Our partnership began with the Magenta Elevate™ First-in-Human Clinical Study in High-Risk PCI Patients, successfully conducted in Tbilisi, Georgia. This study evaluated the functionality, safety, and initial efficacy of the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) during high-risk percutaneous coronary interventions, laying the foundation for further clinical development of this novel technology.

The Elevate™ pLVAD is a groundbreaking innovation in mechanical circulatory support. This self-expanding, catheter-mounted pump is delivered fully sheathed, over-the-wire, through various minimally invasive 10-French femoral introducer sheaths, and expands to its full operational size only once deployed in the left ventricle.

Thanks to its high expansion ratio, the Elevate™ Pump can deliver blood flows that exceed 5.4 liters per minute, effectively providing the full spectrum of left ventricular support in acute cardiac patients. The unique combination of low-profile access and high-output performance positions the Elevate™ Pump as a significant advancement in percutaneous cardiac support technologies. As Magenta Medical’s clinical development programs continues to expand, Clinical Accelerator looks forward to continuing our collaboration. We wish Magenta Medical all the success in advancing the Elevate™ System through upcoming clinical trials and regulatory milestones, ultimately bringing this innovative technology to patients in need.

Clinical Accelerator is proud to announce its ongoing collaboration with Autonomix on the clinical study “Pain Mitigation in Pancreatic Adenocarcinoma: Neurolysis via Transvascular Radiofrequency Ablation,” currently being conducted in Uzbekistan. This study explores a minimally invasive approach to addressing the severe pain experienced by patients with pancreatic adenocarcinoma, a critical and unmet medical need.

Autonomix’s novel technique utilizes transvascular radiofrequency ablation to perform targeted neurolysis, offering an innovative solution to improve quality of life for patients. Early results from the trial indicate an 63% reduction in pain at the 7-day follow-up in the first 15 subjects, highlighting the potential of this groundbreaking therapy (Autonomix Press Release). Clinical Accelerator is proud to support this critical work by providing expertise in trial management, regulatory support and patient recruitment.

For more information on Autonomix, visit https://www.autonomix.com/

About Clinical Accelerator

Clinical Accelerator is a global CRO specializing in innovative medical devices studies across all major therapeutic areas. Our goal is to accelerate clinical development programs of international medical technology companies by facilitating early entry into the clinic and ensuring fast and efficient implementation of First-in-Human (FIH) and Early Feasibility Studies (EFS). With extensive experience in trial execution, Clinical Accelerator partners with companies to bring groundbreaking solutions to patients worldwide.

About Autonomix

Autonomix develops advanced neuro-modulatory solutions to address critical medical needs. Their innovative therapies aim to improve outcomes and enhance quality of life for patients with complex conditions.

Welcome to Clinical Accelerator’s blog – a forum for you to explore current views on how to run clinical trials smarter, faster, more efficiently and with less expense, and share your concerns.

I am Cher Thornhill – the Editor of Clinical Accelerator’s blog. This is an exciting time for Clinical Accelerator as we launch our new website, logo and our one and only blog.

Challenges

In this stream, I will report on and discuss the challenges shared by all clinical research organisations and investigative sites in the process of taking pharmaceutical and medical device concepts to market. Patient recruitment and associated delays can be the source of many troubles, costs, trial failures and sleepless nights before we even start, as most of you well know.

We will keep an eye and report on the latest clinical trial dilemmas and fixes as they emerge. The aim is to develop a community in which you will use the blog as a place to learn from the experiences of other clinical research professionals and investigators, propose topics you would like information on, and submit your own post(s) for others to absorb – which could be a tip to make the clinical trial process more smooth, fast and less costly, or a moan about the latest problem that is proving difficult to solve.

The Clinical Conversation

Alongside Clinical Accelerator’s team members Vlada Iegorova and President Dr Nikolai Nikitin, I will update you and begin the conversation designed to answer your questions.

At the moment, I envision that I’m writing for a community of people and professionals interested in the smart delivery of clinical trials. In response to this idea and all topics discussed, please feel free to leave your comments on our blog site or write to info@clinicalaccelerator.com to let me know your thoughts and submit your own posts to the conversation.

Cher Thornhill